ClinicalTrialsFinder
RecruitingNCT06718816

Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD

A Long-term Follow-up Study to Evaluate the Safety and Effectivity of AL-001 Ophthalmic Injection in Subjects with Wet Age-related Mecular Degeneration (wAMD)

Sponsor

Beijing Anlong Biopharmaceutical Co., Ltd.

Enrollment

21 participants

Start Date

Dec 9, 2024

Study Type

OBSERVATIONAL

Conditions

Wet Age-related Macular Degeneration (wAMD)

Summary

This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.

Eligibility

Min Age: 50 Years

Inclusion Criteria3

  • The subjects enrolled in AL-001 study and received AL-001 ophthalmic injection.
  • The subject or their legal representative agrees to participate in this study and signs a written ICF.
  • The subjects are willing and able to follow planned visits and procedures.

Exclusion Criteria1

  • None

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Chinese Academy of Medical Sciences & Peking Union Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06718816